Skip to main content
SpringerLink
Log in

Disturbance of Iron Metabolism as a Contributing Factor to SN Hyperechogenicity in Parkinson’s Disease: Implications for Idiopathic and Monogenetic Forms

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

A number of investigations have provided evidence for a central role of iron in the pathogenesis of Parkinson’s disease (PD). Recently it could be demonstrated that iron related changes of the substantia nigra may be one important factor contributing to the hyperechogenicity typicall visualized by transcranial sonography in idiopathic PD. Moreover, also patients with monogenetically caused PD show this hyperechogenicity, although to a lesser extent. According to numerous findings and experiments it seems plausible that iron also contributes to the pathophysiological cascades in the monogenetic forms of PD. Therefore, it is not only essential to acknowledge the pivotal role of iron for PD, but also to enhance the effort in finding therapeutic strategies to prevent the impact of iron on neurodegenerative processes. Moreover, early detection of subjects at risk is essential for the application of therapeutic strategies at a stage at which neuroprotection is still possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Youdim MB, Green AR (1978) Iron deficiency and neurotransmitter synthesis and function. Proc Nutr Soc 37:173–179

    Article  PubMed  CAS  Google Scholar 

  2. Youdim MB (1988) Iron in the brain: implications for Parkinson’s and Alzheimer’s diseases. Mt Sinai J Med 55:97–101

    PubMed  CAS  Google Scholar 

  3. Youdim MB, Ben-Shachar D, Riederer P (1991) Iron in brain function and dysfunction with emphasis on Parkinson’s disease. Eur Neurol 31(Suppl 1):34–40

    PubMed  Google Scholar 

  4. Youdim MB, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson’s disease. Mov Disord 8:1–12

    Article  PubMed  CAS  Google Scholar 

  5. Youdim MB, Ben-Shachar D (1987) Minimal brain damage induced by early iron deficiency: modified dopaminergic neurotransmission. Isr J Med Sci 23:19–25

    PubMed  CAS  Google Scholar 

  6. Hallgren B, Sourander P (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3:41–51

    Article  PubMed  CAS  Google Scholar 

  7. Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W, Fischer M, Ogris E (1988) Biochemical fundamentals of Parkinson’s disease. Mt Sinai J Med 55:21–28

    PubMed  CAS  Google Scholar 

  8. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199–205

    Article  PubMed  CAS  Google Scholar 

  9. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515–520

    Article  PubMed  CAS  Google Scholar 

  10. Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60:273–281

    PubMed  CAS  Google Scholar 

  11. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63:793–807

    Article  PubMed  CAS  Google Scholar 

  12. Youdim MB, Ben-Shachar D, Riederer P (1989) Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 126:47–54

    PubMed  CAS  Google Scholar 

  13. Riederer P, Youdim MBH (eds) (1993) Iron in central nervous system disorders. Springer, Vienna

    Google Scholar 

  14. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P (2004) The relevance of iron in the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci 1012:193–208

    Article  PubMed  CAS  Google Scholar 

  15. Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J (1999) Increased basal ganglia iron levels in Huntington disease. Arch Neurol 56:569–574

    Article  PubMed  CAS  Google Scholar 

  16. Hutchinson M, Raff U (2000) Structural changes of the substantia nigra in Parkinson’s disease as revealed by MR imaging. AJNR Am J Neuroradiol 21:697–701

    PubMed  CAS  Google Scholar 

  17. Mondino F, Filippi P, Magliola U, Duca S (2002) Magnetic resonance relaxometry in Parkinson’s disease. Neurol Sci 23(Suppl 2):S87–S88

    Article  PubMed  Google Scholar 

  18. Brass SD, Chen NK, Mulkern RV, Bakshi R (2006) Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 17:31–40

    Article  PubMed  Google Scholar 

  19. Michaeli S, Oz G, Sorce DJ, Garwood M, Ugurbil K, Majestic S, Tuite P (2007) Assessment of brain iron and neuronal integrity in patients with Parkinson’s disease using novel MRI contrasts. Mov Disord 22:334–340

    Article  PubMed  Google Scholar 

  20. Berg D, Behnke S, Walter U (2006) Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall Med 27:12–19

    Article  PubMed  CAS  Google Scholar 

  21. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 45:182–184

    PubMed  CAS  Google Scholar 

  22. Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol 248:684–689

    Article  PubMed  CAS  Google Scholar 

  23. Walter U, Wittstock M, Benecke R, Dressler D (2002) Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson’s disease. J Neural Transm 109:191–196

    Article  PubMed  CAS  Google Scholar 

  24. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19:1196–1202

    Article  PubMed  Google Scholar 

  25. Miwa H, Okawa M, Kondo T (2006) [Echogenicity of the substantia nigra in Parkinson’s disease: its relation to clinical findings]. No To Shinkei 58:199–204

    PubMed  Google Scholar 

  26. Spiegel J, Hellwig D, Mollers MO, Behnke S, Jost W, Fassbender K, Samnick S, Dillmann U, Becker G, Kirsch CM (2006) Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson’s disease. Brain 129:1188–1193

    Article  PubMed  Google Scholar 

  27. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D (2003) Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes. Neurology 60:74–77

    Article  PubMed  CAS  Google Scholar 

  28. Behnke S, Berg D, Naumann M, Becker G (2005) Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 76:423–425

    Article  PubMed  CAS  Google Scholar 

  29. Berg D, Grote C, Rausch WD, Maurer M, Wesemann W, Riederer P, Becker G (1999) Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25:901–904

    Article  PubMed  CAS  Google Scholar 

  30. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031

    PubMed  CAS  Google Scholar 

  31. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999–1005

    Article  PubMed  Google Scholar 

  32. Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, Tampellini D, Riederer P, Gerlach M, Becker G (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20:1278–1285

    Article  PubMed  Google Scholar 

  33. Gandon Y, Guyader D, Heautot JF, Reda MI, Yaouanq J, Buhe T, Brissot P, Carsin M, Deugnier Y (1994) Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 193:533–538

    PubMed  CAS  Google Scholar 

  34. Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov Disord 20:383–385

    Article  PubMed  Google Scholar 

  35. Brooks DJ (1998) The early diagnosis of Parkinson’s disease. Ann Neurol 44:S10–S18

    Article  PubMed  CAS  Google Scholar 

  36. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P (2004) PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage 23:1–16

    Article  PubMed  CAS  Google Scholar 

  37. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G (2001) Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 50:463–467

    Article  PubMed  CAS  Google Scholar 

  38. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G (2001) Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56:13–17

    Article  PubMed  CAS  Google Scholar 

  39. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:10–15

    Article  PubMed  Google Scholar 

  40. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D (2006) Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson’s disease. Mov Disord 21:94–98

    Article  PubMed  Google Scholar 

  41. Ruprecht-Dorfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL, Lange KW, Becker G (2003) Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. Neuroimage 18:416–422

    Article  PubMed  Google Scholar 

  42. Borie C, Gasparini F, Verpillat P, Bonnet AM, Agid Y, Hetet G, Brice A, Durr A, Grandchamp B (2002) Association study between iron-related genes polymorphisms and Parkinson’s disease. J Neurol 249:801–804

    Article  PubMed  Google Scholar 

  43. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D (2004) Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63:1912–1917

    PubMed  CAS  Google Scholar 

  44. Felletschin B, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Sommer U, Zeiler B, Becker G, Riess O, Berg D (2003) Screening for mutations of the ferritin light and heavy genes in Parkinson’s disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett 352:53–56

    Article  PubMed  CAS  Google Scholar 

  45. Deplazes J, Schobel K, Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Becker G, Riess O, Berg D (2004) Screening for mutations of the IRP2 gene in Parkinson’s disease patients with hyperechogenicity of the substantia nigra. J Neural Transm 111:515–521

    Article  PubMed  CAS  Google Scholar 

  46. Akbas N, Hochstrasser H, Deplazes J, Tomiuk J, Bauer P, Walter U, Behnke S, Riess O, Berg D (2006) Screening for mutations of the HFE gene in Parkinson’s disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett 407:16–19

    Article  PubMed  CAS  Google Scholar 

  47. Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, Becker G (2001) Brain iron pathways and their relevance to Parkinson’s disease. J Neurochem 79:225–236

    Article  PubMed  CAS  Google Scholar 

  48. Klomp LW, Gitlin JD (1996) Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet 5:1989–1996

    Article  PubMed  CAS  Google Scholar 

  49. Kohno S, Miyajima H, Takahashi Y, Inoue Y (2000) Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics 2:237–238

    Article  PubMed  CAS  Google Scholar 

  50. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J (2001) Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 28:350–354

    Article  PubMed  CAS  Google Scholar 

  51. Bosio S, De Gobbi M, Roetto A, Zecchina G, Leonardo E, Rizzetto M, Lucetti C, Petrozzi L, Bonuccelli U, Camaschella C (2002) Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 100:2246–2248

    Article  PubMed  CAS  Google Scholar 

  52. Thompson K, Menzies S, Muckenthaler M, Torti FM, Wood T, Torti SV, Hentze MW, Beard J, Connor J (2003) Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res 71:46–63

    Article  PubMed  CAS  Google Scholar 

  53. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, Drake SK, Miller G, Abu-Asab M, Tsokos M, Switzer R III, Grinberg A, Love P, Tresser N, Rouault TA (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 27:209–214

    Article  PubMed  CAS  Google Scholar 

  54. Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB (2005) Gene expression profiling of sporadic Parkinson’s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 1053:356–375

    Article  PubMed  CAS  Google Scholar 

  55. Gasser T (2005) Genetics of Parkinson’s disease. Curr Opin Neurol 18:363–369

    Article  PubMed  CAS  Google Scholar 

  56. Klein UC, Hilker R, Benecke R, Pramstaller PP, Dressler D (2004) Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19:1445–1449

    Article  PubMed  Google Scholar 

  57. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047

    Article  PubMed  CAS  Google Scholar 

  58. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18:106–108

    Article  PubMed  CAS  Google Scholar 

  59. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:841

    Article  PubMed  CAS  Google Scholar 

  60. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164–173

    Article  PubMed  CAS  Google Scholar 

  61. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem 277:16116–16123

    Article  PubMed  CAS  Google Scholar 

  62. Hashimoto M, Rockenstein E, Crews L, Masliah E (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases. Neuromolecular Med 4:21–36

    Article  PubMed  CAS  Google Scholar 

  63. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985–989

    Article  PubMed  CAS  Google Scholar 

  64. Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts—an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20:253–257

    Article  PubMed  CAS  Google Scholar 

  65. Lee EN, Lee SY, Lee D, Kim J, Paik SR (2003) Lipid interaction of alpha-synuclein during the metal-catalyzed oxidation in the presence of Cu2+ and H2O2. J Neurochem 84:1128–1142

    Article  PubMed  CAS  Google Scholar 

  66. Stadtman ER (2001) Protein oxidation in aging and age-related diseases. Ann N Y Acad Sci 928:22–38

    Article  PubMed  CAS  Google Scholar 

  67. Cole NB, Murphy DD, Lebowitz J, Di Noto L, Levine RL, Nussbaum RL (2005) Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J Biol Chem 280:9678–9690

    Article  PubMed  CAS  Google Scholar 

  68. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson’s disease. Ann Neurol 44:S72–S84

    PubMed  CAS  Google Scholar 

  69. Gaeta A, Hider RC (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146:1041–1059

    Article  PubMed  CAS  Google Scholar 

  70. Castellani RJ, Siedlak SL, Perry G, Smith MA (2000) Sequestration of iron by Lewy bodies in Parkinson’s disease. Acta Neuropathol (Berl) 100:111–114

    Article  CAS  Google Scholar 

  71. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D (2001) alpha-Synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 30:1163–1170

    Article  PubMed  CAS  Google Scholar 

  72. Junn E, Mouradian MM (2002) Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 320:146–150

    Article  PubMed  CAS  Google Scholar 

  73. Petrucelli L, O’Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36:1007–1019

    Article  PubMed  CAS  Google Scholar 

  74. Tsai YC, Fishman PS, Thakor NV, Oyler GA (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 278:22044–22055

    Article  PubMed  CAS  Google Scholar 

  75. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, Abbas N, Gu WJ, Hirsch EC, Rooney T, Ruberg M, Brice A (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12:517–526

    Article  PubMed  CAS  Google Scholar 

  76. Jiang H, Ren Y, Zhao J, Feng J (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13:1745–1754

    Article  PubMed  CAS  Google Scholar 

  77. Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J, Wiegers K, Schwinger E, Pramstaller PP, Breakefield XO, Ozelius LJ, Vieregge P, Klein C (2002) Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol 51:621–625

    Article  PubMed  CAS  Google Scholar 

  78. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC (2003) Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60:796–801

    PubMed  CAS  Google Scholar 

  79. Mata IF, Lockhart PJ, Farrer MJ (2004) Parkin genetics: one model for Parkinson’s disease. Hum Mol Genet 13(Spec No 1):R127–133

    Article  PubMed  CAS  Google Scholar 

  80. Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, Ho MW, Lim TM, Soong TW, Pletnikova O, Troncoso J, Dawson VL, Dawson TM, Lim KL (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin’s protective function. Hum Mol Genet 14:3885–3897

    Article  PubMed  CAS  Google Scholar 

  81. Jimenez Del Rio M, Moreno S, Garcia-Ospina G, Buritica O, Uribe CS, Lopera F, Velez-Pardo C (2004) Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis. Mov Disord 19:324–330

    Article  Google Scholar 

  82. Pawlyk AC, Giasson BI, Sampathu DM, Perez FA, Lim KL, Dawson VL, Dawson TM, Palmiter RD, Trojanowski JQ, Lee VM (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 278:48120–48128

    Article  PubMed  CAS  Google Scholar 

  83. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 304:1328–1331

    Article  PubMed  CAS  Google Scholar 

  84. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, Lipton SA (2004) Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 101:10810–10814

    Article  PubMed  CAS  Google Scholar 

  85. Lipton SA, Nakamura T, Yao D, Shi ZQ, Uehara T, Gu Z (2005) Comment on “S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function”. Science 308:1870; author reply 1870

    Article  PubMed  CAS  Google Scholar 

  86. Lim KL, Dawson VL, Dawson TM (2002) The genetics of Parkinson’s disease. Curr Neurol Neurosci Rep 2:439–446

    Article  PubMed  Google Scholar 

  87. Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26–S36; discussion S36–S28

    Article  PubMed  CAS  Google Scholar 

  88. Jahngen-Hodge J, Obin MS, Gong X, Shang F, Nowell TR Jr, Gong J, Abasi H, Blumberg J, Taylor A (1997) Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 272:28218–28226

    Article  PubMed  CAS  Google Scholar 

  89. Nishikawa K, Li H, Kawamura R, Osaka H, Wang YL, Hara Y, Hirokawa T, Manago Y, Amano T, Noda M, Aoki S, Wada K (2003) Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304:176–183

    Article  PubMed  CAS  Google Scholar 

  90. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J Biol Chem 279:13256–13264

    Article  PubMed  CAS  Google Scholar 

  91. Ciechanover A, Brundin P (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40:427–446

    Article  PubMed  CAS  Google Scholar 

  92. Zhou W, Zhu M, Wilson MA, Petsko GA, Fink AL (2006) The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J Mol Biol 356:1036–1048

    Article  PubMed  CAS  Google Scholar 

  93. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A (2004) DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2:e362

    Article  PubMed  CAS  Google Scholar 

  94. Schapira AH (2006) Etiology of Parkinson’s disease. Neurology 66:S10–S23

    PubMed  Google Scholar 

  95. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56:1441–1444

    Article  PubMed  CAS  Google Scholar 

  96. Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson’s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306–325

    Article  PubMed  CAS  Google Scholar 

  97. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46:254–263

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hertie Institute of Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Strasse 3, 72076, Tubingen, Germany

    Daniela Berg

Authors
  1. Daniela Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela Berg.

Additional information

Special issue dedicated to Dr. Moussa Youdim

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berg, D. Disturbance of Iron Metabolism as a Contributing Factor to SN Hyperechogenicity in Parkinson’s Disease: Implications for Idiopathic and Monogenetic Forms. Neurochem Res 32, 1646–1654 (2007). https://doi.org/10.1007/s11064-007-9346-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-007-9346-5

Keywords

Search

Navigation